It was identified that pERα-S118 and pERα-S167 were expressed in a proportion of tamoxifen-resistant breast tumors, and that their expression did not exhibit any correlation with the age, menopausal status, TNM (tumor size, axillary lymph node staging) stage or ER and PR status of the patient. The gene discussed is ESR1; the disease is neoplasm.